Institut Catala d'Oncologia Badalona, Hospital Germans Trias I Pujol
Institut Catala d'Oncologia Badalona, Hospital Germans Trias I Pujol
Badalona, Spain4 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-09-22 | NCT06712316 | |
| A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy | Bronchiolitis Obliterans, bronchial disorder, bronchiolitis, bronchiolitis obliterans syndrome, bronchitis, cryptogenic organizing pneumonia, graft versus host disease, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-08-25 | NCT06821542 | |
| Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neoplasms by Site, Neoplasms, Multiple Primary, Thoracic Neoplasms, autosomal dominant Parkinson disease 4, bronchial neoplasm, bronchogenic carcinoma, endocrine system disorder, hereditary disease, hereditary neoplastic syndrome, lethal congenital contracture syndrome 2, lung disorder, lung neoplasm, malignant endocrine neoplasm, multiple endocrine neoplasia, multiple endocrine neoplasia type 2A, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, type 1 diabetes mellitus 12 | Recruiting | Phase 1 | 2026-07-22 | NCT05142189 | |
| Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) | Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) | Active, not recruiting | Phase 3 | 2026-04-01 | NCT06430866 |